Floatz logo

Bafisontamab

Unresectable/Metastatic Colorectal Cancer

Shanghai EpimAb Biotherapeutics Co., Ltd.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Unresectable/Metastatic Colorectal Cancer cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Bafisontamab is also rated in:

colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →
EGFR Mutation-Related TumorsDormant
CCC
Indicative ·
48 / 100
View asset →
Advanced Lung Non-Small Cell CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →